Implications of Dose and Response to Long-Term Granulocyte Colony Stimulating Factor (G-CSF) in a Patient with Severe Congenital Neutropenia
Rosenberg et al evaluated patients with severe congenital neutropenia who received long-term therapy with granulocyte colony stimulating factor (G-CSF). A patient who responds poorly to higher doses is at greater risk for a poor outcome. The authors are from the National Cancer Institute (NCI) and multiple institutions in the United States, Canada, Aurstralia and Europe.
To read more or access our algorithms and calculators, please log in or register.